Non-invasive · AI-driven · Continuous
HepaTrac is a wearable sensor patch that reads your liver’s biomarkers around the clock. Real-time AI analysis. Alerts before damage becomes irreversible.
Americans living with undetected liver disease
Combined liver diagnostics and treatment market
Wearable liver monitoring devices on the market today
The Problem
The liver has no nerve endings. It fails without signalling pain or discomfort. Current tools are invasive, episodic, or simply out of reach for the populations that need monitoring most.
01
The liver fails without signalling pain or discomfort. Most patients learn about their condition only after irreversible damage has occurred. There is no early warning.
02
Invasive, expensive, and not viable for routine screening. There is no practical tool today for monitoring high-risk patients continuously over time.
03
People with obesity, type 2 diabetes, or heavy alcohol use face significant liver risk. Almost none receive ongoing liver surveillance. The at-risk population is well-defined. The monitoring infrastructure simply does not exist.
The Platform
Four integrated components working together — from skin-level sensor to clinical action — without a lab visit, a blood draw, or a wait.
01 — The Patch
A wearable patch worn on the skin. It extracts interstitial fluid continuously, pain-free. Applied once, working around the clock without interruption.
02 — The Engine
Sensors read ammonia, IL-6, cortisol and other liver-specific markers at configurable intervals. Analysis runs against your personal baseline, not a population average. That distinction matters enormously in clinical practice.
03 — The Alert
When readings deviate from baseline, both patient and clinician are notified immediately. Not in a monthly report. Right now, while there is still time to intervene.
04 — The Loop
Detection automatically triggers a referral pathway from sensor reading through telehealth review to in-person treatment. The patient does not have to navigate it alone.
The system is designed to require as little from the patient as possible and as much from the technology as possible.
01
Patient applies the HepaTrac patch. Microneedles extract interstitial fluid continuously. Painless from the first moment.
02
Sensors measure liver biomarkers at regular, configurable intervals. Continuous monitoring throughout the day and night.
03
The AI compares readings against the patient’s personal baseline and generates a risk score. It learns what normal looks like for that specific person.
04
If thresholds are crossed, both the patient app and clinician dashboard are alerted immediately. A telehealth visit is triggered before the situation becomes a crisis.
Competitive Landscape
Every existing test is either invasive, episodic, or incomplete. HepaTrac is the only option that satisfies all five criteria simultaneously.
| Criteria | Liver Biopsy | Fibroscan | FIB-4 Blood Test | Hepatrac |
|---|---|---|---|---|
| Non-invasive | × | ✓ | ✓ | ✓ |
| Continuous monitoring | × | × | × | ✓ |
| Liver-specific | ✓ | ✓ | Partial | ✓ |
| AI-driven alerts | × | × | × | ✓ |
| Wearable and at-home | × | × | Partial | ✓ |
| Low cost | × | × | ✓ | ✓ |
Market Opportunity
The U.S. accounts for 43% of global liver diagnostics spending. The MASLD and MASH epidemic is driving wearable monitoring demand up more than 10% per year.
Combined liver TAM of $84B. Two independent market categories, diagnostics and treatments, both validating the commercial scale of the unmet clinical need HepaTrac addresses.
The Team
The founders have cleared FDA devices in multiple countries, published hundreds of peer-reviewed papers in liver disease, and built companies totalling over $500M in exits.
Co-founder and CEO
Multiple exits totalling over $500M. FDA 510(k) clearances in three countries. Co-authored several high-tech patents. He has built medical devices from prototype to market before. More than once.
Co-founder and Chairman
Magna cum laude, Yale. MD from Johns Hopkins. Training at Georgetown, Stanford, and the NIH. Nearly 200 peer-reviewed publications in liver disease. Former Distinguished Professor and Director of Hepatology. Fellow of the Royal College of Physicians, London.
Advisory Board
Six senior hepatologists. Business advisors with $50B+ in IPO experience and CEO exits exceeding $1B. Clinical trial and regulatory expertise across multiple geographies.
Dr. Adrian Di Bisceglie MD
Dr. Geoffrey Dusheiko MD
George Devaux MBA
Dr. James Lewis MD
Dr. Naga Chalasani MD
Donald Jordan JD
Dr. Joseph Lim MD
Dr. Tarek Hassanein MD
Ali Habib MBA/MITS
We know exactly where we are. The SAFE round closes now. Clinical trials begin Q3. Beta testing Q4. Product launch and Series A by Q2 2027.
For Investors
$5M cap
20% discount
SAFE note
Request the full deck or book a call with Daniel directly. No obligation. No pitch theatre. Just the facts.
For Clinicians
We are building a group of hepatology and gastroenterology practices to pilot HepaTrac in real clinical settings. Tell us about your practice and we will be in touch.
For Talent
CTO, hardware engineers, software engineers, and clinical experts. If you want to work on something that genuinely matters, see the open roles.
